483 related articles for article (PubMed ID: 21236312)
1. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus.
Torresi J; Johnson D; Wedemeyer H
J Hepatol; 2011 Jun; 54(6):1273-85. PubMed ID: 21236312
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic vaccines against hepatitis C virus.
Xue J; Zhu H; Chen Z
Infect Genet Evol; 2014 Mar; 22():120-9. PubMed ID: 24462908
[TBL] [Abstract][Full Text] [Related]
3. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
[TBL] [Abstract][Full Text] [Related]
4. Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection.
Bull RA; Leung P; Gaudieri S; Deshpande P; Cameron B; Walker M; Chopra A; Lloyd AR; Luciani F
J Virol; 2015 May; 89(10):5478-90. PubMed ID: 25740982
[TBL] [Abstract][Full Text] [Related]
5. Success and failure of virus-specific T cell responses in hepatitis C virus infection.
Neumann-Haefelin C; Thimme R
Dig Dis; 2011; 29(4):416-22. PubMed ID: 21894013
[TBL] [Abstract][Full Text] [Related]
6. [The development of therapeutic vaccine for hepatitis C virus].
Kimura K; Kohara M
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1451-7. PubMed ID: 23064054
[TBL] [Abstract][Full Text] [Related]
7. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.
Encke J; Radunz W; Eisenbach C; Geib J; Gehrke S; Pfaff E; Stremmel W
Eur J Clin Invest; 2007 May; 37(5):396-406. PubMed ID: 17461986
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of hepatitis C virus protein epitopes for vaccine development.
Koshy R; Inchauspé G
Trends Biotechnol; 1996 Oct; 14(10):364-9. PubMed ID: 8987634
[TBL] [Abstract][Full Text] [Related]
9. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
[TBL] [Abstract][Full Text] [Related]
10. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus.
Puig M; Mihalik K; Tilton JC; Williams O; Merchlinsky M; Connors M; Feinstone SM; Major ME
Hepatology; 2006 Sep; 44(3):736-45. PubMed ID: 16941702
[TBL] [Abstract][Full Text] [Related]
11. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus.
Feinstone SM; Hu DJ; Major ME
Clin Infect Dis; 2012 Jul; 55 Suppl 1():S25-32. PubMed ID: 22715210
[TBL] [Abstract][Full Text] [Related]
12. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design.
Smyk-Pearson S; Tester IA; Lezotte D; Sasaki AW; Lewinsohn DM; Rosen HR
J Infect Dis; 2006 Aug; 194(4):454-63. PubMed ID: 16845628
[TBL] [Abstract][Full Text] [Related]
13. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses.
Houghton M
Immunol Rev; 2011 Jan; 239(1):99-108. PubMed ID: 21198667
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus--T-cell responses and viral escape mutations.
Petrovic D; Dempsey E; Doherty DG; Kelleher D; Long A
Eur J Immunol; 2012 Jan; 42(1):17-26. PubMed ID: 22125159
[TBL] [Abstract][Full Text] [Related]
15. Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.
Grollo L; Torresi J; Drummer H; Zeng W; Williamson N; Jackson DC
Antivir Ther; 2006; 11(8):1005-14. PubMed ID: 17302370
[TBL] [Abstract][Full Text] [Related]
16. Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting.
Rollier C; Verschoor EJ; Paranhos-Baccala G; Drexhage JA; Verstrepen BE; Berland JL; Himoudi N; Barnfield C; Liljestrom P; Lasarte JJ; Ruiz J; Inchauspe G; Heeney JL
J Infect Dis; 2005 Sep; 192(5):920-9. PubMed ID: 16088843
[TBL] [Abstract][Full Text] [Related]
17. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development.
Lamonaca V; Missale G; Urbani S; Pilli M; Boni C; Mori C; Sette A; Massari M; Southwood S; Bertoni R; Valli A; Fiaccadori F; Ferrari C
Hepatology; 1999 Oct; 30(4):1088-98. PubMed ID: 10498664
[TBL] [Abstract][Full Text] [Related]
18. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection.
Thimme R; Binder M; Bartenschlager R
FEMS Microbiol Rev; 2012 May; 36(3):663-83. PubMed ID: 22142141
[TBL] [Abstract][Full Text] [Related]
19. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
[TBL] [Abstract][Full Text] [Related]
20. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
